1. Introduction
===============

Magnetic resonance imaging (MRI) is widely used in patients with breast cancer, with several indications because of its high sensitivity.^\[[@R1],[@R2]\]^ The basic principles of breast MRI, as currently used, rely on the difference between enhancement levels for normal and malignant tissue on T1-weighted dynamic contrast-enhanced MRI (DCE-MRI) sequences. Based on these principles, DCE-MRI has been an essential tool for the detection, diagnosis, and monitoring of breast malignancies.^\[[@R3]--[@R6]\]^ However, there are 2 major issues with this technique. First, breast MRI is known to have a relatively low specificity because normal tissue and benign lesions are also enhanced.^\[[@R7],[@R8]\]^ However, through the combined use of mammography alongside DCE-MRI, as well as technological advances such as diffusion, perfusion, and spectroscopy, several recent publications have reported an improved specificity.^\[[@R6],[@R9]--[@R11]\]^ Second, the requirement for intravenous administration of a gadolinium-based contrast agent increases the associated time, costs, and potential toxicity of a breast DCE-MRI examination. Recently, several researchers have reported that use of intravenous gadolinium-based contrast agents is associated with neuronal tissue deposition even without renal dysfunction.^\[[@R12]\]^ These factors make it difficult to accept a wider use of contrast-enhanced MRI, especially for screening purposes.

Because of concerns about possible contrast material-related problems, various approaches to breast MRI without contrast agents, both for lesion detection and characterization, have been proposed.^\[[@R13]\]^ Diffusion-weighted imaging (DWI) is one of the most promising MRI techniques with which to improve the diagnostic specificity of breast MRI without the use of contrast material.^\[[@R2],[@R14],[@R15]\]^ Several researchers have reported that combinations of unenhanced MRI including DWI show good diagnostic performance.^\[[@R13],[@R16],[@R17]\]^ Furthermore, DWI provides quantitative information by measuring the apparent diffusion coefficient (ADC), which is significantly lower in breast cancers compared to benign lesions.^\[[@R18]--[@R20]\]^ However, to replace the DCE-MRI, detection of lesions on DWI should be preceded. Following this, a quantitative ADC measurement can be performed. Nevertheless, little is known about the factors influencing the degree of detectability of lesions on DWI or the diffusion background signal in patients with invasive breast cancer.^\[[@R21],[@R22]\]^

The purpose of this study was to identify the factors influencing the degree of detectability of lesions on DWI and diffusion background signal in cases of invasive breast cancer.

2. Materials and methods
========================

2.1. Patients
-------------

Institutional review board approval was obtained for this study and informed patient consent was waived due to the retrospective nature of the study.

Between January 2013 and May 2013, 282 patients who had a histological diagnosis of an invasive ductal carcinoma presented as a mass on preoperative MRI by using a 1.5 T scanner were identified. We excluded cases for which MRI was performed after diagnosis by vacuum-assisted biopsy or excisional biopsy (n = 53). Patients treated with neoadjuvant chemotherapy (n = 42), those who had bilateral malignancies (n = 5), and those who had a history of prior breast malignancies (n = 15) were also excluded. Finally, 167 cancers from 167 women age 27 to 77 years (mean, 51 years; range, 27--77 years) were included in this study.

At the time of performing the MRI, patients were asked questions about their menopausal status, the regularity of their menstrual cycles (if the patient was premenopausal), and the date of their last menstrual period. The menstrual cycle was divided into 4 weeks; Week 1 began on the 1st day of menstruation.

2.2. MRI protocol
-----------------

MRI was performed using a 1.5-T system (Achieva; Philips Medical Systems, Best, The Netherlands) for 167 lesions with dedicated bilateral phased array breast coils. Images of both breasts were acquired with the patient in the prone position. The backbone MRI sequence consisted of a turbo spin-echo T1- and T2-weighted sequence, a single-shot spin-echo planar diffusion-weighted sequence, and a 3-dimensional DCE sequence. The DCE-MRI parameters included repetition time (TR) = 6.5, echo time (TE) = 2.5, slice thickness = 1.5 mm, flip angle = 10°, matrix size = 376 × 374, and field of view = 320 × 320 mm. Before contrast agent injection, DW images were obtained for both breasts with diffusion-sensitizing gradients applied along 3 orthogonal directions. These images were used to synthesize isotropic axial DW images under 2 b values (0 and 750 s/mm^2^).^\[[@R23]\]^ The DWI parameters included TR = 15,000, TE = 66.7, slice thickness = 3 mm, matrix size = 156 × 158, and field of view = 300 × 300 mm.

Axial DCE-MRI included 1 precontrast and 6 postcontrast dynamic series. The first-phase images of postcontrast dynamic series were obtained 30 s after contrast injection, and the rest 5 phases were obtained at 60 s intervals until 330 s. After dynamic series, images were subtracted. A 0.1 mmol/kg bolus of Gadobutrol (Gadovist; Bayer Healthcare Pharmaceutical, Berlin, Germany) was injected for dynamic contrast imaging, after a 20-mL saline flush.

2.3. Image analysis
-------------------

All MR images were retrospectively reviewed and interpreted by 2 radiologists (ESK and SYH with 10 and 8 years of experience in breast MR images, respectively) in consensus. The reviewers were blinded to the clinicopathological findings including mammographic density, hormonal receptor status, and menopausal status. Tumor size was defined as the maximum diameter of the tumor in the second phase after contrast injection. In the case of multifocal or multicentric disease, only the index lesion was analyzed.

The radiologists evaluated the tumor detectability of DWI, and positive detection was defined as high signal intensity than that of the surrounding parenchyma on DW images with 2 b values. DCE-MR images were referenced to find the target malignant mass. When positive detection was identified on DWI, the detectability was scored on DWI with b value of 750 s/mm^2^ by consensus of 2 radiologists. The score was determined according to the 5-point scale as follows: 1 = not detectable, 2 = slight, 3 = fair, 4 = moderate, and 5 = excellent (Fig. [1](#F1){ref-type="fig"}). Similarly, detectability on contrast-enhanced subtracted T1-weighted images was also rated using the same 5-point scale. The amount of background parenchymal enhancement (BPE) and diffusion background signals were visually assessed and classified according to a 4-point scale: 1 = minimum, 2 = mild, 3 = moderate, and 4 = marked enhancement (Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).^\[[@R24]\]^ Mammographic density of the contralateral breast was scored according to a 4-point scale (1 = a predominantly fatty breast, 2 = a scattered fibroglandular fatty breast, 3 = a heterogeneous dense breast, and 4 = an extremely dense breast).

![Axial diffusion-weighted magnetic resonance images (b value, 750 s/mm^2^) according to the 5-point scale (1: not detectable, 2: slight, 3: fair, 4: moderate, 5: excellent). (A) Score 1. (B) Score 2. (C) Score 3. (D) Score 4. (E) Score 5. All masses were left-sided.](medi-95-e4086-g001){#F1}

![Invasive ductal carcinoma of the left breast in a 55-y-old woman. (A) Axial contrast-enhanced T1-weighted subtraction image shows a 27-mm mass (arrows). Background parenchymal enhancement score of contralateral breast was 1. The detectability score on subtraction image was 2. (B) Axial diffusion-weighted magnetic resonance imaging (b value, 750 s/mm^2^) shows a high signal intensity mass (arrows). Diffusion background signal was rated as score 1. Score of diffusion detectability was 5.](medi-95-e4086-g002){#F2}

![Invasive ductal carcinoma of the left breast in a 60-y-old woman. (A) Axial contrast-enhanced T1-weighted subtraction image shows a 20-mm mass (arrows). Background parenchymal enhancement score of contralateral breast was 2. The detectability score on subtraction image was 5. (B) Axial diffusion-weighted magnetic resonance imaging (b value, 750 s/mm^2^) shows subtle high signal intensity mass. Diffusion background signal was rated as score 4. Score of diffusion detectability was 2.](medi-95-e4086-g003){#F3}

The 2 radiologists measured ADC values in consensus. Using a dedicated picture archiving and communication system workstation, the ADC values were obtained by placing the region of interest (ROI) within the border of area on the ADC map, corresponding to enhancing solid portion of targeted lesion demonstrated on the first or second phase of DCE-MRI. The ROI was drawn on the slice in which the tumor showed the greatest diameter, excluding the cystic or necrotic parts of the tumor. The mean size of the ROIs was 60.2 mm^2^ (range, 10.8--343.8 mm^2^).

2.4. Pathological data
----------------------

Pathological reports of either breast-conserving surgery or mastectomy specimens were reviewed to determine estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2) status, as well as tumor type, histological grade, Ki-67 status, lymphovascular invasion, and the presence of extensive intraductal components. The criteria for ER and PR positivity were ≥1% of their nuclei stained. Immunohistochemical HER2 scores of 3+ (i.e., strong homogeneous staining) were interpreted as positive. In cases of 2+ scores (i.e., moderate complete membranous staining in ≥10% of tumor cells), silver-enhanced in situ hybridization (SISH) was used to determine HER2 amplification (gene copy number \> 6 or HER2/chromosome 17 ratio \> 2.2). Molecular subtypes of breast cancer were classified into luminal A (ER-positive and/or PR-positive, HER2-negative and Ki-67 \< 14%), luminal B (ER-positive and/or PR-positive, HER2-negative, and Ki-67 ≥ 14% or ER- and/or PR-positive and HER2-positive, irrespective of Ki-67 expression), HER2-enriched (ER-negative, PR-negative, and HER2-positive), and triple-negative breast cancer (ER-negative, PR-negative, and HER2-negative) based on immunohistochemistry or SISH findings of ER, PR, HER2, and Ki-67 expression.

2.5. Statistical analysis
-------------------------

Univariate linear regression was used to identify the factors affecting the degree of detectability of lesions on DWI or the diffusion background signal. Multivariate linear regression with stepwise selection was used to select best-fit parameters that were associated with diffusion detectability or diffusion background signals. A stepwise procedure was used such that variables were added if *P* \< 0.2 and were removed if *P* \> 0.2.

All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC), and a *P* value of \<0.05 was considered to indicate a statistically significant difference.

3. Results
==========

The mean lesion size was 19.5 mm (range, 6--75 mm). The mean ADC value was 1.023 × 10^−3^ (range, 0.582--1.914 × 10^−3^). Characteristics of patients included in this study are shown in Table [1](#T1){ref-type="table"}. Out of 167 lesions, 20 (12.0%) were not detected on DWI. One hundred sixteen of the patients (69.5%) had mammographically dense breasts. Eighty-nine (53.3%) women were postmenopausal.

###### 

Patients' characteristics.

![](medi-95-e4086-g004)

3.1. Analysis of factors influencing the degree of detectability of lesions on DWI
----------------------------------------------------------------------------------

The univariate analysis of factors affecting the degree of diffusion detectability of lesions is shown in Table [2](#T2){ref-type="table"}. The lesion size, with larger lesions being easier to detect, affected DWI detectability (*P* = 0.001). While BPE and mammographic density did not affect the diffusion detectability score (*P* = 0.322 and 0.191, respectively), the diffusion background signal significantly decreased the diffusion detectability (*P* \< 0.0001). Menopausal status and menstrual cycle did not affect the diffusion detectability (*P* = 0.433 and 0.242, respectively). The diffusion detectability score did not show a statistically significant difference according to molecular subtype (*P* = 0.281). The higher the detectability scores for contrast-enhanced T1-weighted subtraction images, the higher the detectability scores were for DWI (*P* = 0.000). On multivariate analysis with stepwise selection, diffusion background signal and histological grade were associated with diffusion detectability (*P* \< 0.0001 and *P* \< 0.0001, respectively) (Table [3](#T3){ref-type="table"}).

###### 

Univariate linear regression analysis for factors affecting the diffusion detectability.
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###### 

Multivariate linear regression analysis for factors affecting diffusion detectability.
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3.2. Analysis of factors influencing the degree of diffusion background signal
------------------------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the univariate analysis of factors affecting the degree of diffusion background signal. The degree of diffusion background signal was statistically significantly affected by age (*P* \< 0.0001), BPE (*P* \< 0.0001), mammographic density (*P* = 0.002), and menopausal status (*P* \< 0.0001). As age increased, the diffusion background signal decreased. Similarly, premenopausal women showed higher scores of diffusion background signal than postmenopausal women. BPE and mammographic density were negatively correlated with diffusion background signal. In a multivariate analysis with stepwise selection, when the other covariates were held constant, BPE was correlated with the degree of diffusion background signals on DWI (*P* \< 0.0001) (Table [5](#T5){ref-type="table"}).

###### 

Univariate linear regression analysis for factors affecting diffusion background signal.
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###### 

Multivariate linear regression analysis for factors affecting diffusion background signal.

![](medi-95-e4086-g008)

4. Discussion
=============

Until now, most studies of DWI with quantitative measurement of ADC have focused on the differentiation between benign and malignant lesions or on correlations with pathological findings.^\[[@R19],[@R25],[@R26]\]^ One strong advantage of DWI is its quite high sensitivity for breast cancer detection without the need for a contrast material injection. One recent meta-analysis calculated an overall sensitivity of 0.84 (0.82--0.87) and a specificity of 0.79 (0.75--0.82) for DWI of the breast.^\[[@R27]\]^

Due to increasing interest in breast MRI as a screening method, Kuhl et al^\[[@R28]\]^ suggested using abbreviated breast MRI, which consists of a first postcontrast subtracted image and a maximum-intensity projection, as a novel approach to breast cancer screening. This protocol needs just 3 min for imaging acquisition and shows good diagnostic accuracy. However, because of various drawbacks related to DCE-MRI, including the use of a contrast agent, several studies have evaluated the diagnostic performance of unenhanced MRI including DWI.^\[[@R13],[@R16],[@R17]\]^ Trimboli et al^\[[@R17]\]^ evaluated the diagnostic performance of unenhanced MRI in detecting breast cancer. In their study, DWI played a crucial role in cancer detection, increasing the sensitivity from 59--62% to 70--76% when adding DWI to T1-weighted imaging. According to Baltzer et al,^\[[@R13]\]^ the sensitivity of unenhanced MRI was 86% to 93% while that of contrast-enhanced MRI was 96.5% to 98.3%; the respective specificities were 85.2% and 92.6%. Partridge et al showed 89% of mammographically and clinically occult malignancies were hyperintense on b = 600 s/mm^2^ DWI. However, this feature was not restricted to malignancies, with 81% of benign lesions also demonstrating hyperintensity.^\[[@R29]\]^ In another study by Partridge et al,^\[[@R30]\]^ they concluded that, when looking into the differentiation of breast masses, there is 10% improvement in the positive predictive value when combining DWI with DCE-MRI. Several reports have also demonstrated that ADC values of DWI allowed for the differentiation between malignant and benign breast lesions by demonstrating significant differences, with malignancy yielding a low ADC value and benignity yielding a high value.^\[[@R20],[@R31]--[@R33]\]^ According to these results, they suggested that many mammographically and clinically occult breast cancers can be detected on DWI, and benign and malignant lesions can be separated by using an ADC threshold.

Based on these prior studies, we designed this study to evaluate the factors affecting the degree of lesion detectability on DWI. In our study, detectability was not influenced by molecular subtype, menopausal status, menstrual cycle, mammographic density, BPE, or lesion size. In general, our results agreed with existing published studies. Youk et al^\[[@R25]\]^ reported ADC values changed according to molecular subtype but detectability scores did not. In terms of BPE, Iacconi et al found that the visibility of breast lesions on DWI was not influenced by the amount of breast tissue and BPE,^\[[@R34]\]^ although the amount of breast tissue affected the quantitative measurement of ADC. Several studies researched the effect of the menstrual cycle or menopausal status on DWI. Most of them found that quantitative measurement of DWI in normal premenopausal breast was different according to the menstrual cycle phase; however, there was no statistical significance.^\[[@R34]--[@R36]\]^ These findings supported the impression of insignificance to DWI of menopausal status, menstrual cycle, and BPE, which is usually supposed regarding menstrual cycle timing in young women^\[[@R24],[@R37]\]^ and is known to be a weakness of DCE-MRI. Further, mammographic density did not make a significant difference on DWI. Interestingly, although detectability scores on DWI were worse than those on contrast-enhanced T1-weighted subtraction images in the present study and in previous studies,^\[[@R13]\]^ 104 (62.3%) of 167 lesions were scored as a 4 or 5. Therefore, our results suggest that DWI could be a potential breast cancer detection method, without using contrast material, which gives consistent results regardless of menstrual cycle, menopausal status, or mammographically dense breasts. However, at this point, additional technical advances or adjunctive imaging modality, such as mammography, are still needed to reduce the amount of false positive and false negative results due to the low spatial resolution of DWI. Recently, Bickelhaupt et al reported that DWI with background suppression and unenhanced morphological sequences may be useful as a fast and noninvasive approach to assess the likelihood of malignancy for suspicious lesions detected on screening X-ray mammograms and to reduce the number of unnecessary biopsies.^\[[@R38]\]^

Diffusion background signal is a concept that corresponds to mammographic density or BPE on MRI. We proposed this concept because we realized that increased diffusion background signal diminished the detectability score. The diffusion background signal was independently associated with diffusion detectability on both univariate and multivariate analyses (*P* \< 0.0001). Unlike diffusion detectability, BPE was the most important factor affecting the diffusion background signal on multivariate analysis (*P* \< 0.0001).

Our results about the diffusion background signal are quite similar to those found for ^99m^Tc-methoxyisobutylisonitrile (MIBI) on breast-specific gamma imaging (BSGI). A recent study by Yoon et al showed that high background MIBI uptake on BSGI was significantly correlated with a younger age (*P* \< 0.001), premenopausal status (*P* = 0.003), dense breast (*P* \< 0.001), and marked BPE (*P* \< 0.001). However, on multivariate analysis, only BPE remained a significant factor affecting background MIBI uptake (*P* \< 0.001).^\[[@R39]\]^ In our univariate analysis, younger age (*P* \< 0.0001), premenopausal status (*P* \< 0.0001), dense breast (*P* \< 0.0001), and high BPE (*P* \< 0.0001) were correlated with an increased diffusion background signal. On multivariate analysis, only BPE was significantly correlated with the diffusion background signal (*P* \< 0.0001). The actual mechanism whereby BPE affects diffusion background signals is unclear. We suspect that hormonal changes could be involved in this process.

Our results are supportive of the idea that DWI may have potential as an alternative noncontrast MRI technique. However, breast DWI is still a challenging technique because of its intrinsic low spatial resolution. Scanning at higher field strength may enable a DWI acquisition with thinner slices that can better demonstrate small or diffuse lesions.^\[[@R40]--[@R42]\]^ Using more advanced DWI sequences, such as the readout-segmented echo planar imaging, improves the signal to noise ratio of DWI.^\[[@R41]\]^ Optimization of acquisition parameters and technical developments, such as advanced breast coil hardware with 16 and 32 channels,^\[[@R43]\]^ could improve contrast and spatial resolution, allowing for a higher diagnostic performance of DWI. However, because contrast-enhanced MRI can give many critical pieces of information, such as the kinetic pattern or local staging of the tumor, it could not be entirely replaced in most cases.

There were several limitations to this study. First, all lesions included in this study were biopsy-confirmed malignancies. Also, we often referenced contrast-enhanced MR images to find a target lesion. Thus, we could not evaluate the actual diagnostic performance of DWI. However, the goal of our study was not to investigate the actual diagnostic performance of DWI but to find the factors affecting the degree of detectability. Second, we restricted the included lesions with strict criteria to evaluate DWI under homogenous condition. Therefore, our results might be less robust to generalization to all lesions or all machines. Third, we did not calculate intra- or inter-observer variability for diffusion detectability or diffusion background signal score. Fourth, we did not include information about hormone-related therapy, which might affect mammographic breast density and BPE on MRI. Because this study was retrospective in nature, the available medical records about hormonal replacement therapy were not reliable. Finally, DWI detectability was evaluated using 5-point scale by 2 reviewers in consensus. Although earlier studies have also analyzed data by using this 5-point scale system, this method of data evaluation could still be subjectively biased.^\[[@R25],[@R36]\]^

In conclusion, diffusion detectability was not influenced by BPE, mammographic density, menopausal status, or menstrual cycle. The diffusion background signal affected the detectability on DWI. BPE on MRI was the most important factor affecting the diffusion background signal on DWI.

Abbreviations: ADC = apparent diffusion coefficient, BPE = background parenchymal enhancement, DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging, DWI = diffusion-weighted imaging, ER = estrogen receptor, HER2 = human epidermal growth factor receptor type 2, IDC = invasive ductal carcinoma, LMP = last menstrual period, PR = progesterone receptor, SISH = silver-enhanced in situ hybridization.
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